UK markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.5000-0.0200 (-0.57%)
As of 02:23PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 37.16M
Enterprise value 42.62M
Trailing P/E 0.68
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.90
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.15

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-51.11%
S&P500 52-week change 326.36%
52-week high 312.0000
52-week low 31.9000
50-day moving average 34.2160
200-day moving average 33.7005

Share statistics

Avg vol (3-month) 3451.98k
Avg vol (10-day) 31.35M
Shares outstanding 510.56M
Implied shares outstanding 610.56M
Float 86.45M
% held by insiders 126.87%
% held by institutions 13.64%
Shares short (30 Apr 2024) 4486.17k
Short ratio (30 Apr 2024) 41.63
Short % of float (30 Apr 2024) 45.63%
Short % of shares outstanding (30 Apr 2024) 44.61%
Shares short (prior month 28 Mar 2024) 4424.54k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 302 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-118.07%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.14M
Net income avi to common (ttm)-25.65M
Diluted EPS (ttm)5.2000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.32M
Total cash per share (mrq)0.15
Total debt (mrq)6.78M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.18
Book value per share (mrq)-1.70

Cash flow statement

Operating cash flow (ttm)-19.24M
Levered free cash flow (ttm)-9.49M